TNNT2 and peripheral arterial disease: Although no randomized control trials explored the predictive role of hs-cTn solely in patients with PAD, PAD patients were included in a 2017 TRA 2°P–TIMI 50 biomarker substudy by Eisen et al. [19], evaluating the prognostic value of hs-cTnT in patients with stable atherosclerotic cardiovascular disease.